Brief: FDA Approves Durvalumab In Combination With Bacillus Calmette-Guerin
28/05/2026 20:19
BRIEF-FDA Approves Durvalumab In Combination With Bacillus Calmette-Guerin May 28 (Reuters) - FDA:
FDA APPROVES DURVALUMAB IN COMBINATION WITH BACILLUS CALMETTE-GUERIN FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains